The current financial score of Fennec Pharmaceuticals Inc is 8.63. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 17.87M, representing a year-over-year increase of 85.18%, while its net profit experienced a year-over-year increase of 162.60%.
The current valuation score of Fennec Pharmaceuticals Inc is 9.73. Its current P/E ratio is -36.27, which is -406.88% below the recent high of 111.31 and -1111.85% above the recent low of -439.57.
The current earnings forecast score of Fennec Pharmaceuticals Inc is 8.33. The average price target is 17.67, with a high of 20.00 and a low of 16.00.
The current price momentum score of Fennec Pharmaceuticals Inc is 4.30. Currently, the stock price is trading between the resistance level at 12.23 and the support level at 9.57, making it suitable for range-bound swing trading.
The current institutional shareholding score of Fennec Pharmaceuticals Inc is 5.00. The latest institutional shareholding proportion is 53.51%, representing a quarter-over-quarter decrease of 16.42%.
The current risk assessment score of Fennec Pharmaceuticals Inc is 3.20. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.